Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von PlusUltra 

Discuss Verrica Pharmaceuticals

Verrica Pharmaceuticals

WKN: A2JPEV / Symbol: VRCA / Name: Verrica Pharmaceuticals / Aktie / Small Cap /

4,70 €
-1,59 %

Sell Verrica Pharmaceuticals

Einschätzung Buy
Rendite (%) -33,33 %
Kursziel 9,25
Veränderung
Endet am 23.08.24

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Ratings data for VRCA provided by MarketBeat

Einschätzung Buy
Rendite (%) -25,29 %
Kursziel 11,34
Veränderung
Endet am 12.10.24

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for VRCA provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,12 %
Kursziel 7,49
Veränderung
Endet am 10.11.24

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target lowered by analysts at Needham & Company LLC from $10.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for VRCA provided by MarketBeat

Einschätzung Buy
Rendite (%) -49,02 %
Kursziel 9,18
Veränderung
Endet am 15.12.24

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $10.00 price target on the stock.
Ratings data for VRCA provided by MarketBeat

Einschätzung Buy
Rendite (%) -41,37 %
Kursziel 12,02
Veränderung
Endet am 01.03.25

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target raised by analysts at HC Wainwright from $12.00 to $13.00. They now have a "buy" rating on the stock.
Ratings data for VRCA provided by MarketBeat

Einschätzung Buy
Rendite (%) -73,74 %
Kursziel 14,81
Veränderung
Endet am 14.05.25

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target raised by analysts at Needham & Company LLC from $8.00 to $16.00. They now have a "buy" rating on the stock.
Ratings data for VRCA provided by MarketBeat

Einschätzung Buy
Rendite (%) -73,74 %
Kursziel 12,96
Veränderung
Endet am 14.05.25

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target raised by analysts at HC Wainwright from $13.00 to $14.00. They now have a "buy" rating on the stock.
Ratings data for VRCA provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,69 %
Kursziel 10,95
Veränderung
Endet am 15.08.25

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $12.00. They now have a "buy" rating on the stock.
Ratings data for VRCA provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 11,83
Veränderung
Endet am 15.08.25

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target lowered by analysts at Royal Bank of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Ratings data for VRCA provided by MarketBeat